{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,27]],"date-time":"2025-10-27T12:39:17Z","timestamp":1761568757221,"version":"build-2065373602"},"reference-count":27,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2016,4,1]],"date-time":"2016-04-01T00:00:00Z","timestamp":1459468800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2016,4,1]],"date-time":"2016-04-01T00:00:00Z","timestamp":1459468800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinical-genitourinary-cancer.com","clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Clinical Genitourinary Cancer"],"published-print":{"date-parts":[[2016,4]]},"DOI":"10.1016\/j.clgc.2015.11.003","type":"journal-article","created":{"date-parts":[[2015,11,12]],"date-time":"2015-11-12T09:38:24Z","timestamp":1447321104000},"page":"139-148","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":2,"title":["Characterizations of Clinical and Therapeutic Histories for Men With Prostate Cancer-Specific Mortality"],"prefix":"10.1016","volume":"14","author":[{"given":"Allie E.","family":"Steinberger","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Elisa M.","family":"Ledet","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Eric","family":"Luk","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Patrick","family":"Cotogno","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Michael","family":"Stolten","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Daniel","family":"Desmond","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Allison","family":"Feibus","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jonathan","family":"Silberstein","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Oliver","family":"Sartor","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.clgc.2015.11.003_bib1","first-page":"9","article-title":"Cancer statistics, 2014","volume":"64","author":"Siegel","year":"2014","journal-title":"CA Cancer J Clin"},{"key":"10.1016\/j.clgc.2015.11.003_bib2","doi-asserted-by":"crossref","first-page":"243","DOI":"10.1016\/S0025-6196(11)61005-7","article-title":"Prostate cancer: a practical approach to current management of recurrent disease","volume":"82","author":"Walczak","year":"2007","journal-title":"Mayo Clin Proc"},{"key":"10.1016\/j.clgc.2015.11.003_bib3","doi-asserted-by":"crossref","first-page":"983","DOI":"10.2165\/10898600-000000000-00000","article-title":"Castration-resistant prostate cancer: current and emerging treatment strategies","volume":"70","author":"Di Lorenzo","year":"2010","journal-title":"Drugs"},{"key":"10.1016\/j.clgc.2015.11.003_bib4","first-page":"147","article-title":"Selecting treatment for high-risk, localized prostate cancer: the case for radical prostatectomy","volume":"4","author":"Lepor","year":"2002","journal-title":"Rev Urol"},{"key":"10.1016\/j.clgc.2015.11.003_bib5","first-page":"CD005247","article-title":"Chemotherapy for hormone-refractory prostate cancer","author":"Shelley","year":"2006","journal-title":"Cochrane Database Syst Rev"},{"key":"10.1016\/j.clgc.2015.11.003_bib6","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1056\/NEJMoa1213755","article-title":"Alpha emitter radium-223 and survival in metastatic prostate cancer","volume":"369","author":"Parker","year":"2013","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.clgc.2015.11.003_bib7","doi-asserted-by":"crossref","first-page":"1995","DOI":"10.1056\/NEJMoa1014618","article-title":"Abiraterone and increased survival in metastatic prostate cancer","volume":"364","author":"de Bono","year":"2011","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.clgc.2015.11.003_bib8","doi-asserted-by":"crossref","first-page":"1755","DOI":"10.1056\/NEJMoa1405095","article-title":"Enzalutamide in metastatic prostate cancer before chemotherapy","volume":"371","author":"Beer","year":"2014","journal-title":"N\u00a0Engl J Med"},{"year":"2009","series-title":"SEER cancer statistics review, 1975-2007","key":"10.1016\/j.clgc.2015.11.003_bib9"},{"key":"10.1016\/j.clgc.2015.11.003_bib10","doi-asserted-by":"crossref","first-page":"182","DOI":"10.1111\/bju.12212","article-title":"Causes of death in men with prostate cancer: an analysis of 50,000 men from the Thames Cancer Registry","volume":"112","author":"Chowdhury","year":"2013","journal-title":"BJU Int"},{"key":"10.1016\/j.clgc.2015.11.003_bib11","doi-asserted-by":"crossref","first-page":"3062","DOI":"10.1002\/cncr.26392","article-title":"Prostate cancer in the elderly: frequency of advanced disease at presentation and disease-specific mortality","volume":"118","author":"Scosyrev","year":"2012","journal-title":"Cancer"},{"key":"10.1016\/j.clgc.2015.11.003_bib12","doi-asserted-by":"crossref","first-page":"5768","DOI":"10.1002\/cncr.27503","article-title":"Prostate-specific antigen screening for prostate cancer and the risk of overt metastatic disease at presentation: analysis of trends over time","volume":"118","author":"Scosyrev","year":"2012","journal-title":"Cancer"},{"key":"10.1016\/j.clgc.2015.11.003_bib13","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1016\/j.eururo.2013.09.024","article-title":"The prognostic importance of metastatic site in men with metastatic castration-resistant prostate cancer","volume":"65","author":"Pond","year":"2014","journal-title":"Eur Urol"},{"key":"10.1016\/j.clgc.2015.11.003_bib14","first-page":"1128","article-title":"Lymph node positive prostate cancer: long-term survival data after radical prostatectomy","volume":"171","author":"Zwergel","year":"2004","journal-title":"J\u00a0Urol"},{"key":"10.1016\/j.clgc.2015.11.003_bib15","unstructured":"ClinicalTrials.gov. Androgen ablation therapy with or without chemotherapy in treating patients with metastatic prostate cancer. NLM identifier: NCT00309985."},{"key":"10.1016\/j.clgc.2015.11.003_bib16","doi-asserted-by":"crossref","first-page":"1502","DOI":"10.1056\/NEJMoa040720","article-title":"Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer","volume":"351","author":"Tannock","year":"2004","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.clgc.2015.11.003_bib17","doi-asserted-by":"crossref","first-page":"1513","DOI":"10.1056\/NEJMoa041318","article-title":"Docetaxel and estramustine compared with mitoxantrone and prednisone for advanced refractory prostate cancer","volume":"351","author":"Petrylak","year":"2004","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.clgc.2015.11.003_bib18","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1186\/1756-8722-4-18","article-title":"Progression of metastatic castrate-resistant prostate cancer: impact of therapeutic intervention in the post-docetaxel space","volume":"4","author":"Sartor","year":"2011","journal-title":"J\u00a0Hematol Oncol"},{"key":"10.1016\/j.clgc.2015.11.003_bib19","doi-asserted-by":"crossref","first-page":"605","DOI":"10.1007\/s10147-014-0746-7","article-title":"Predictive factors for severe and febrile neutropenia during docetaxel chemotherapy for castration-resistant prostate cancer","volume":"20","author":"Shigeta","year":"2015","journal-title":"Int J Clin Oncol"},{"key":"10.1016\/j.clgc.2015.11.003_bib20","first-page":"233","article-title":"Differences in treatment patterns among patients with castration-resistant prostate cancer treated by oncologists versus urologists in a US managed care population","volume":"3","author":"Engel-Nitz","year":"2011","journal-title":"Cancer Manag Res"},{"key":"10.1016\/j.clgc.2015.11.003_bib21","article-title":"The diffusion of docetaxel in patients with metastatic prostate cancer","volume":"107","author":"Unger","year":"2014","journal-title":"J Natl Cancer Inst"},{"issue":"suppl","key":"10.1016\/j.clgc.2015.11.003_bib22","article-title":"Efficacy and toxicity of docetaxel in elderly men with castrate-resistant metastatic prostate cancer","volume":"28","author":"Shepard","year":"2010","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.clgc.2015.11.003_bib23","doi-asserted-by":"crossref","first-page":"167","DOI":"10.3816\/CGC.2003.n.025","article-title":"Weekly docetaxel in elderly patients with prostate cancer: efficacy and toxicity in patients at least 70 years of age compared with patients younger than 70 years","volume":"2","author":"Beer","year":"2003","journal-title":"Clin Prostate Cancer"},{"key":"10.1016\/j.clgc.2015.11.003_bib24","doi-asserted-by":"crossref","first-page":"3176","DOI":"10.1016\/j.ejca.2013.06.008","article-title":"Analysis of docetaxel therapy in elderly (>\/=70 years) castration resistant prostate cancer patients enrolled in the Netherlands Prostate Study","volume":"49","author":"Gerritse","year":"2013","journal-title":"Eur J Cancer"},{"key":"10.1016\/j.clgc.2015.11.003_bib25","doi-asserted-by":"crossref","first-page":"303","DOI":"10.1038\/pcan.2012.13","article-title":"Toxicity in patients receiving adjuvant docetaxel\u00a0+ hormonal treatment after radical radiotherapy for intermediate or high-risk prostate cancer: a preplanned safety report of the SPCG-13 trial","volume":"15","author":"Kellokumpu-Lehtinen","year":"2012","journal-title":"Prostate Cancer Prostatic Dis"},{"key":"10.1016\/j.clgc.2015.11.003_bib26","doi-asserted-by":"crossref","first-page":"483","DOI":"10.1093\/jjco\/hyt040","article-title":"Risk factors for severe adverse effects and treatment-related deaths in Japanese patients treated with irinotecan-based chemotherapy: a postmarketing survey","volume":"43","author":"Shiozawa","year":"2013","journal-title":"Jpn J Clin Oncol"},{"key":"10.1016\/j.clgc.2015.11.003_bib27","first-page":"785","article-title":"Analysis of the risk factors for myelosuppression after concurrent chemoradiotherapy for patients with advanced non-small cell lung cancer","volume":"21","author":"Jiang","year":"2013","journal-title":"Support Care Cancer"}],"container-title":["Clinical Genitourinary Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S155876731500302X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S155876731500302X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,27]],"date-time":"2025-10-27T11:25:52Z","timestamp":1761564352000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S155876731500302X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,4]]},"references-count":27,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2016,4]]}},"alternative-id":["S155876731500302X"],"URL":"https:\/\/doi.org\/10.1016\/j.clgc.2015.11.003","relation":{},"ISSN":["1558-7673"],"issn-type":[{"type":"print","value":"1558-7673"}],"subject":[],"published":{"date-parts":[[2016,4]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Characterizations of Clinical and Therapeutic Histories for Men With Prostate Cancer-Specific Mortality","name":"articletitle","label":"Article Title"},{"value":"Clinical Genitourinary Cancer","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.clgc.2015.11.003","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2016 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}